| NCT Number | NCT04669496 |
| Lead Sponsor | Shanghai Zhongshan Hospital
Collaborators: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai Public Health Clinical Center, RenJi Hospital, Shenzhen University General Hospital, Sir Run Run Shaw Hospital, Tang-Du Hospital, First Affiliated Hospital of Wenzhou Medical University, The First Affiliated Hospital of Zhengzhou University, The First Affiliated Hospital of Anhui Medical University, First Hospital of China Medical University, Eastern Hepatobiliary Surgery Hospital, First Affiliated Hospital Xi'an Jiaotong University, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, First Affiliated Hospital of Guangxi Medical University, The Affiliated Hospital of Qingdao University, Peking Union Medical College Hospital, Meng Chao Hepatobiliary Hospital of Fujian Medical University, The First Affiliated Hospital of University of Science and Technology of China, Cancer Hospital of Guangxi Medical University, Tongji Hospital, Zhejiang Provincial People's Hospital, The Second Affiliated Hospital of Kunming Medical University, Sichuan Provincial People's Hospital, Taizhou Hospital, Shaoxing People's Hospital, The First Hospital of Hebei Medical University |
| Conditions | Intrahepatic Cholangiocarcinoma, PD1 Antibody, Lenvatinib, Gemox Chemotherapy |
| Enrollment | 178 participants |
| Start Date | 2021-01-20 |
| Primary Completion | 2025-04-30 (estimated) |
| Study Completion | 2026-12 (estimated) |
| Updated on ClinicalTrials.gov | 2025-09-04 |